trending Market Intelligence /marketintelligence/en/news-insights/trending/eaPdOTnPm73ic6iOaFy5Zw2 content esgSubNav
In This List

Portola Pharmaceuticals plans $200M common stock offering

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Portola Pharmaceuticals plans $200M common stock offering

Portola Pharmaceuticals Inc. is planning an underwritten public offering of $200 million of its common shares.

Goldman Sachs & Co. LLC, Citigroup, Cowen, and William Blair are acting as joint book-running manager in the offering, with Oppenheimer & Co. Inc. as lead manager. The underwriters will be granted an option to buy up to an additional $30 million common shares in the transaction.

South San Francisco, Calif.-based Portola Pharmaceuticals is developing therapies for serious blood-related disorders.